Raymond Alexanian

24.7k total citations · 3 hit papers
226 papers, 14.3k citations indexed

About

Raymond Alexanian is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Raymond Alexanian has authored 226 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Hematology, 117 papers in Molecular Biology and 98 papers in Oncology. Recurrent topics in Raymond Alexanian's work include Multiple Myeloma Research and Treatments (171 papers), Cancer Treatment and Pharmacology (63 papers) and Protein Degradation and Inhibitors (56 papers). Raymond Alexanian is often cited by papers focused on Multiple Myeloma Research and Treatments (171 papers), Cancer Treatment and Pharmacology (63 papers) and Protein Degradation and Inhibitors (56 papers). Raymond Alexanian collaborates with scholars based in United States, Greece and United Kingdom. Raymond Alexanian's co-authors include Meletios Α. Dimopoulos, Bart Barlogie, Kay Delasalle, Donna Weber, B Barlogie, Lon Smith, Lia A. Moulopoulos, Joshua Epstein, Barthel Barlogie and P Selvanayagam and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Raymond Alexanian

224 papers receiving 13.5k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

2004 569 citations Sundar Jagannath, Bart Barlogie et al. British Journal of Haematology profile →
Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents

1984 500 citations Bart Barlogie, Raymond Alexanian et al. profile →
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1969 380 citations Raymond Alexanian profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raymond Alexanian United States	70	10.5k	7.1k	6.0k	3.2k	1.9k	226	14.3k
Jean‐Luc Harousseau France	69	11.0k 1.1×	8.8k 1.2×	7.0k 1.2×	2.6k 0.8×	2.2k 1.1×	319	15.8k
Mario Boccadoro Italy	60	10.9k 1.0×	8.3k 1.2×	7.4k 1.2×	2.2k 0.7×	1.7k 0.9×	479	15.9k
Régis Bataille France	71	10.0k 1.0×	8.5k 1.2×	7.5k 1.3×	2.5k 0.8×	2.0k 1.0×	269	16.9k
Hervé Avet‐Loiseau France	67	12.7k 1.2×	11.3k 1.6×	7.4k 1.2×	2.7k 0.8×	1.9k 1.0×	374	17.0k
Joan Bladé Spain	61	12.1k 1.2×	9.3k 1.3×	6.9k 1.2×	2.4k 0.8×	997 0.5×	324	14.8k
Michel Attal France	66	13.2k 1.3×	8.4k 1.2×	7.4k 1.2×	1.8k 0.6×	1.5k 0.8×	322	16.2k
Michèle Cavo Italy	62	11.3k 1.1×	7.7k 1.1×	6.7k 1.1×	2.2k 0.7×	957 0.5×	557	14.5k
Jerry A. Katzmann United States	54	5.4k 0.5×	5.1k 0.7×	2.6k 0.4×	2.6k 0.8×	1.4k 0.7×	171	10.6k
Xavier Leleu France	53	6.9k 0.7×	6.4k 0.9×	4.4k 0.7×	3.0k 0.9×	2.1k 1.1×	457	11.4k
Ramón García‐Sánz Spain	53	5.5k 0.5×	4.0k 0.6×	3.7k 0.6×	3.1k 1.0×	2.4k 1.3×	337	9.6k

Countries citing papers authored by Raymond Alexanian

Since Specialization

Citations

This map shows the geographic impact of Raymond Alexanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond Alexanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond Alexanian more than expected).

Fields of papers citing papers by Raymond Alexanian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond Alexanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond Alexanian. The network helps show where Raymond Alexanian may publish in the future.

Co-authorship network of co-authors of Raymond Alexanian

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond Alexanian. A scholar is included among the top collaborators of Raymond Alexanian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond Alexanian. Raymond Alexanian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Lorenzo, Ying Guo, Yuhong Zhou, et al.. (2014). Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. Journal of Hematology & Oncology. 7(1). 41–41. 47 indexed citations

Lonial, Sagar, Adam D. Cohen, Jeffrey A. Zonder, et al.. (2011). The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood. 118(21). 2935–2935. 4 indexed citations

Fu, Weijun, Kay Delasalle, Jialei Wang, et al.. (2011). Bortezomib-Cyclophosphamide-Dexamethasone for Relapsing Multiple Myeloma. American Journal of Clinical Oncology. 35(6). 562–565. 10 indexed citations

Jagannath, Sundar, Bart Barlogie, James R. Berenson, et al.. (2008). Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British Journal of Haematology. 143(4). 537–540. 75 indexed citations

Christoforidou, Anna, Rima M. Saliba, Patricia Williams, et al.. (2007). Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes. Biology of Blood and Marrow Transplantation. 13(5). 543–549. 18 indexed citations

Wang, Michael, Yuhong Zhou, Haijun Wang, et al.. (2007). Trend and Geographic Variations in the Incidence of Waldenstrom’s Macroglobulinemia in the United States over 17 Years from 1988 to 2004.. Blood. 110(11). 5174–5174. 1 indexed citations

Wang, Michael, Robert Knight, David S. Siegel, et al.. (2006). Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.. Blood. 108(11). 3553–3553. 14 indexed citations

Richardson, Paul G., Hannah Briemberg, Sundar Jagannath, et al.. (2006). Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. Journal of Clinical Oncology. 24(19). 3113–3120. 480 indexed citations

Anagnostopoulos, Athanasios K., Meletios Α. Dimopoulos, D. Weber, et al.. (2001). High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplantation. 27(10). 1027–1029. 38 indexed citations

10.

Alexanian, Raymond, Kenneth C. Anderson, Bart Barlogie, David Stirling, & Deborah A. Thomas. (2000). Thalidomide in hematologic malignancies: Future directions. Seminars in Hematology. 37. 35–39. 3 indexed citations

11.

Keren, David F., Raymond Alexanian, James A. Goeken, et al.. (1999). Guidelines for Clinical and Laboratory Evaluation of Patients With Monoclonal Gammopathies. Archives of Pathology & Laboratory Medicine. 123(2). 106–107. 82 indexed citations

12.

Barlogie, Bart, Sundar Jagannath, S. Naucke, et al.. (1998). Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone. 1101–11071. 1 indexed citations

13.

Dimopoulos, Meletios Α., D. Weber, Kay Delasalle, Michael J. Keating, & Raymond Alexanian. (1995). Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors. Annals of Oncology. 6(1). 49–52. 57 indexed citations

14.

Dimopoulos, Meletios Α., Donna M. Weber, Jeane P. Hester, et al.. (1994). Intensive Sequential Therapy for VAD-Resistant Multiple Myeloma. Leukemia & lymphoma. 13(5-6). 479–484. 6 indexed citations

15.

Kantarjian, HM, Raymond Alexanian, CA Koller, Razelle Kurzrock, & MJ Keating. (1990). Fludarabine therapy in macroglobulinemic lymphoma. Blood. 75(10). 1928–1931. 2 indexed citations

16.

Quesada, Jorge R., Raymond Alexanian, Razelle Kurzrock, et al.. (1988). Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia. American Journal of Hematology. 29(1). 1–4. 40 indexed citations

17.

Barlogie, Bart & Raymond Alexanian. (1987). Biology and Therapy of Multiple Myeloma. Acta Haematologica. 78(1). 171–174. 8 indexed citations

18.

Barlogie, Bart, et al.. (1986). High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 67(5). 1298–1301. 99 indexed citations

19.

Bonnet, John D., Raymond Alexanian, S. E. Salmon, et al.. (1982). Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.. PubMed. 66(6). 1267–71. 27 indexed citations

20.

Alexanian, Raymond, Judith Nadell, & Clarence P. Alfrey. (1972). Oxymetholone Treatment for the Anemia of Bone Marrow Failure. Blood. 40(3). 353–365. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact